Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.58 |
| ▸ | TP53 | P04637 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338568 | 0.83 | HPGD (0.58) | HPGDTP53MAPTALDH1A1POLB | |
| SCHEMBL2336999 | 0.82 | HPGD (0.49) | HPGDTP53MAPTALDH1A1NPC1 | |
| SCHEMBL2334947 | 0.82 | HPGD (0.62) | HPGDTP53MAPTALDH1A1POLB | |
| SCHEMBL2338834 | 0.80 | HPGD (0.56) | HPGDTP53MAPTNPC1FGFR1 | |
| SCHEMBL23675213 | 0.78 | HPGD (0.72) | HPGDTP53MAPTALDH1A1POLB | |
| SCHEMBL2340607 | 0.78 | HPGD (0.54) | HPGDTP53MAPT | |
| SCHEMBL1379658 | 0.76 | HPGD (0.56) | HPGDTP53MAPTALDH1A1POLB | |
| SCHEMBL2338547 | 0.75 | TP53 (0.47) | HPGDTP53ALDH1A1NPSR1 | |
| SCHEMBL5930067 | 0.71 | FGFR1 (0.43) | HPGDALDH1A1FGFR1 | |
| SCHEMBL1378193 | 0.71 | MAPT (0.58) | HPGDTP53MAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | claimed |
| US-7419995-B2 | N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | claimed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7419995-B2 | N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | HPGD 1642/4885TP53 356/4885MAPT 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.